Evidence map›Paper›PMID 42828480›Full record

ArticleMolecular oncology2026

Engineering IL-4 resistant proinflammatory human myeloid cells for cancer immunotherapy.

Theresa Barberi, Alan D Friedman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Theresa BarberiDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Alan D FriedmanDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-5615-7061

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
American Brain Tumor Association DG2300061Maryland Stem Cell Research Fund 2023-MSCRFD-6101Maryland Stem Cell Research Fund 2025-R2-MSCRFD-00008NCI NIH HHS P30 CA006973NIH HHS P30 CA006973
6 · The paper itself

Abstract

Adoptive transfer of proinflammatory myeloid cells enhances antitumor T-cell responses and limits tumor growth in murine models. Previous work identified transcription factors NF-κB p50 and STAT6 as key regulators whose inactivation enhances the inflammatory potential of murine myeloid cells. Herein, we translate murine findings to human cells and establish methods to generate proinflammatory myeloid cells from human marrow-derived CD34

Indexed as

humanimmunotherapymacrophagesmyeloid cellsNF‐κB p50STAT6

Identifiers

PMID42828480
PMCPMC13633648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.